Thermo Fisher Scientific CD9 Monoclonal Antibody (eBioSN4 (SN4 C3-3A2)), FITC, eBioscience

Applications

Tested Dilution

Publications

Western Blot (WB)

-

View 1 publication 1 publication

Flow Cytometry (Flow)

5 µL (0.125 µg)/test

View 9 publications 9 publications

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Mouse / IgG1, kappa

Recommended Isotype Control

Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), FITC, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

eBioSN4 (SN4 C3-3A2)

Conjugate

FITC FITC FITC

View additional formats

• Unconjugated
• APC
• Biotin
• PE
• PerCP-eFluor 710
• Super Bright 436
• Super Bright 645
• Request custom conjugation

Excitation/Emission Max

498/517 nm View spectra

Form

Liquid

Concentration

5 µL/Test

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2, with 0.2% BSA

Contains

0.09% sodium azide

Storage conditions

4° C, store in dark, DO NOT FREEZE!

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_10698007

Product Specific Information

Description: The eBioSN4 monoclonal antibody reacts with human CD9. CD9 is a 24 kDa member of the tetraspanin family, whose members are characterized by the presence of 4 hydrophobic transmembrane domains. CD9 is expressed in platelets, eosinophils, basophils, pre-B cells, activated T cells and neural cell lines. Furthermore, CD9 expression has been associated with a malignant phenotype, including expression on 90% of non T cell acute lymphoblastic leukemia cells and on 50% of chronic lymphocytic and acute myeloblastic leukemias. In platelets, CD9 is expressed in alpha-granules and through association with the integrin alphaIIb/betaIII plays a role in platelet aggregation, as demonstrated by the use of anti-human CD9 antibodies. CD9 has also been shown to induce the aggregation of pre-B cell lines, and the adhesion and migration of pre-B cells and Schwann cells. Additionally, it has been demonstrated that CD9 is able to provide a co-stimulatory signal for T cells independently of CD28, in the absence of antigen-presenting cells. Binding of the eBioSN4 monoclonal antibody partially cross-blocks binding of another anti-human CD9 monoclonal antibody, MM2/57.

Applications Reported: This eBioSN4 (SN4 C3-3A2) antibody has been reported for use in flow cytometric analysis.

Applications Tested: This eBioSN4 (SN4 C3-3A2) antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.125 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

CD9 antigen is a glycoprotein expressed on the surface of developing B lymphocytes, platelets, monocytes, eosinophils, basophil, stimulated T lymphocytes and by neurons and glial cells in the peripheral nervous system. CD9 belongs to a family of membrane proteins termed tetraspanins which transverse the membrane four times. In pre B cells and platelets, CD9 antigen regulates cell activation and aggregation possibly through an association with the integrin CD41 / CD61 (GPIIb / GPIIIa). CD9 is involved in cell motility, osteoclastogenesis, neurite outgrowth, myotube formation, and sperm-egg fusion, plays roles in cell attachment and proliferation and is necessary for association of heterologous MHC II molecules on the dendritic cell plasma membrane which is important for effective T cell stimulation. CD9 functions in many cellular processes including differentiation, adhesion, and signal transduction, and expression plays a critical role in the suppression of cancer cell motility and metastasis. CD9 is also considered as metastasis suppressor in solid tumors.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.